Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | TTK |
| Gene Name: | TTK |
| Protein Full Name: | Dual specificity protein kinase TTK |
| Alias: | Cancer/testis antigen 96; CT96; EC 2.7.12.1; Esk1; Mps1; MPS1L1; Phosphotyrosine picked threonine-protein kinase; PYT; TTK protein kinase |
| Mass (Da): | 97072 |
| Number AA: | 857 |
| UniProt ID: | P33981 |
| Locus ID: | 7272 |
| COSMIC ID: | TTK |
| Gene location on chromosome: | 6q13-q21; 6q14.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 20418 |
| Percent of cancer specimens with mutations: | 0.98 |
| Normal role description: | TTK is a dual-specificity protein kinase with activity toward serine, threonine and tyrosine residues. TTK was found to have a role in cell cycle progression through regulating centrosome duplication during S-phase. This function was CDK2-mediated by direct activation of TTK. Overexpression or dysregulation of TTK activtiy may promote cancer through aberrant duplication of centrosomes and promotiong of aneuploidy. Mutations in TTK are highly correlated in the development of microsatellite-unstable colorectal cancers. These mutations were typically loss of function frameshift truncation, however the functional relevance of the mutation was still not determined. |
| Commentary on involvement of protein in cancer: | Less than 3% mutation in lung. |